Notice (8): Undefined variable: solution_of_interest [APP/View/Products/view.ctp, line 755]Code Context<!-- BEGIN: REQUEST_FORM MODAL -->
<div id="request_formModal" class="reveal-modal medium" data-reveal aria-labelledby="modalTitle" aria-hidden="true" role="dialog">
<?= $this->element('Forms/simple_form', array('solution_of_interest' => $solution_of_interest, 'header' => $header, 'message' => $message, 'campaign_id' => $campaign_id)) ?>
$viewFile = '/home/website-server/www/app/View/Products/view.ctp'
$dataForView = array(
'language' => 'en',
'meta_keywords' => 'Modification Ac-Lysine,custom epigenetic antibodies,diagenode',
'meta_description' => 'Diagenode offers Modification Ac-Lysine to meet your specific research needs.',
'meta_title' => 'Modification Ac-Lysine | Diagenode',
'product' => array(
'Product' => array(
'id' => '2651',
'antibody_id' => null,
'name' => 'Modification Ac-Lysine',
'description' => '<p><span>For many years, Diagenode has acquired a strong and reliable experience in the production of custom epigenetic antibodies, allowing us to become one of the most reliable partner in several EU projects in this field of studies. Following our success in optimizing and developing our epigenetic antibody production procedures we are able to offer this as a custom service to meet your specific research needs.</span></p>',
'label1' => 'Characteristics',
'info1' => '<ul>
<li><strong>Flexibility:</strong> you can provide us with your protein or with your own peptide or you can choose our custom peptide design/synthesis/coupling service.</li>
<li><strong>Support:</strong> our team of specialists will provide you with free peptide design and top-level advice and support along your immunisation program.</li>
<li><strong>High-Quality products:</strong> our extended immunisation program will ensure you to get more Ab with higher titer and affinity than any other supplier. Moreover at the end of the program you will receive the purified anti-serum.</li>
<li><strong>Extension of partnership:</strong> If you think that your antibody is proven to be of commercial interest, we will be pleased to consider the opportunity to collaborate.</li>
</ul>',
'label2' => '',
'info2' => '',
'label3' => '',
'info3' => '',
'format' => '20 mg',
'catalog_number' => 'pAb-cust-120',
'old_catalog_number' => '',
'sf_code' => '',
'type' => 'FRE',
'search_order' => '04-undefined',
'price_EUR' => '155',
'price_USD' => '185',
'price_GBP' => '140',
'price_JPY' => '26500',
'price_CNY' => '',
'price_AUD' => '460',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => true,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => true,
'last_datasheet_update' => '0000-00-00',
'slug' => 'modification-ac-lysine',
'meta_title' => 'Modification Ac-Lysine | Diagenode',
'meta_keywords' => 'Modification Ac-Lysine,custom epigenetic antibodies,diagenode',
'meta_description' => 'Diagenode offers Modification Ac-Lysine to meet your specific research needs.',
'modified' => '2023-11-24 11:00:49',
'created' => '2015-07-29 16:42:52',
'locale' => 'eng'
),
'Antibody' => array(
'host' => '*****',
'id' => null,
'name' => null,
'description' => null,
'clonality' => null,
'isotype' => null,
'lot' => null,
'concentration' => null,
'reactivity' => null,
'type' => null,
'purity' => null,
'classification' => null,
'application_table' => null,
'storage_conditions' => null,
'storage_buffer' => null,
'precautions' => null,
'uniprot_acc' => null,
'slug' => null,
'meta_keywords' => null,
'meta_description' => null,
'modified' => null,
'created' => null,
'select_label' => null
),
'Slave' => array(),
'Group' => array(),
'Related' => array(),
'Application' => array(),
'Category' => array(),
'Document' => array(
(int) 0 => array(
[maximum depth reached]
)
),
'Feature' => array(),
'Image' => array(
(int) 0 => array(
[maximum depth reached]
)
),
'Promotion' => array(),
'Protocol' => array(),
'Publication' => array(
(int) 0 => array(
[maximum depth reached]
)
),
'Testimonial' => array(),
'Area' => array(),
'SafetySheet' => array()
)
)
$language = 'en'
$meta_keywords = 'Modification Ac-Lysine,custom epigenetic antibodies,diagenode'
$meta_description = 'Diagenode offers Modification Ac-Lysine to meet your specific research needs.'
$meta_title = 'Modification Ac-Lysine | Diagenode'
$product = array(
'Product' => array(
'id' => '2651',
'antibody_id' => null,
'name' => 'Modification Ac-Lysine',
'description' => '<p><span>For many years, Diagenode has acquired a strong and reliable experience in the production of custom epigenetic antibodies, allowing us to become one of the most reliable partner in several EU projects in this field of studies. Following our success in optimizing and developing our epigenetic antibody production procedures we are able to offer this as a custom service to meet your specific research needs.</span></p>',
'label1' => 'Characteristics',
'info1' => '<ul>
<li><strong>Flexibility:</strong> you can provide us with your protein or with your own peptide or you can choose our custom peptide design/synthesis/coupling service.</li>
<li><strong>Support:</strong> our team of specialists will provide you with free peptide design and top-level advice and support along your immunisation program.</li>
<li><strong>High-Quality products:</strong> our extended immunisation program will ensure you to get more Ab with higher titer and affinity than any other supplier. Moreover at the end of the program you will receive the purified anti-serum.</li>
<li><strong>Extension of partnership:</strong> If you think that your antibody is proven to be of commercial interest, we will be pleased to consider the opportunity to collaborate.</li>
</ul>',
'label2' => '',
'info2' => '',
'label3' => '',
'info3' => '',
'format' => '20 mg',
'catalog_number' => 'pAb-cust-120',
'old_catalog_number' => '',
'sf_code' => '',
'type' => 'FRE',
'search_order' => '04-undefined',
'price_EUR' => '155',
'price_USD' => '185',
'price_GBP' => '140',
'price_JPY' => '26500',
'price_CNY' => '',
'price_AUD' => '460',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => true,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => true,
'last_datasheet_update' => '0000-00-00',
'slug' => 'modification-ac-lysine',
'meta_title' => 'Modification Ac-Lysine | Diagenode',
'meta_keywords' => 'Modification Ac-Lysine,custom epigenetic antibodies,diagenode',
'meta_description' => 'Diagenode offers Modification Ac-Lysine to meet your specific research needs.',
'modified' => '2023-11-24 11:00:49',
'created' => '2015-07-29 16:42:52',
'locale' => 'eng'
),
'Antibody' => array(
'host' => '*****',
'id' => null,
'name' => null,
'description' => null,
'clonality' => null,
'isotype' => null,
'lot' => null,
'concentration' => null,
'reactivity' => null,
'type' => null,
'purity' => null,
'classification' => null,
'application_table' => null,
'storage_conditions' => null,
'storage_buffer' => null,
'precautions' => null,
'uniprot_acc' => null,
'slug' => null,
'meta_keywords' => null,
'meta_description' => null,
'modified' => null,
'created' => null,
'select_label' => null
),
'Slave' => array(),
'Group' => array(),
'Related' => array(),
'Application' => array(),
'Category' => array(),
'Document' => array(
(int) 0 => array(
'id' => '677',
'name' => 'Custom Antibody 032010V4',
'description' => 'Datasheet description',
'image_id' => null,
'type' => 'Datasheet',
'url' => 'files/products/antibodies/Custom_Antibody_032010V4.pdf',
'slug' => 'custom-antibody-032010v4',
'meta_keywords' => null,
'meta_description' => null,
'modified' => '2015-07-07 11:47:44',
'created' => '2015-07-07 11:47:44',
'ProductsDocument' => array(
[maximum depth reached]
)
)
),
'Feature' => array(),
'Image' => array(
(int) 0 => array(
'id' => '250',
'name' => 'product/antibodies/antibody.png',
'alt' => 'Mouse IgG',
'modified' => '2020-11-27 07:00:09',
'created' => '2015-07-17 10:12:18',
'ProductsImage' => array(
[maximum depth reached]
)
)
),
'Promotion' => array(),
'Protocol' => array(),
'Publication' => array(
(int) 0 => array(
'id' => '2804',
'name' => 'HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC)',
'authors' => 'Filipa Lopes-Coelho, Sofia Gouveia-Fernandes, Luís G Gonçalves, Carolina Nunes, Inês Faustino, Fernanda Silva, Ana Félix, Sofia A Pereira, Jacinta Serpa',
'description' => '<p>Chemoresistance to platinum-based antineoplastic agents is a consistent feature among ovarian carcinomas; however, whereas high-grade serous carcinoma (OSC) acquires resistance during chemotherapy, ovarian clear cell carcinoma (OCCC) is intrinsically resistant. The main objective of this study was to explore, in vitro and in vivo, if hepatocyte nuclear factor 1β (HNF1β) and glutaminolysis contribute for the resistance of OCCC to carboplatin through the intrinsically increased GSH bioavailability. To disclose the role of HNF1β, experiments were also performed in an OSC cell line, which does not express HNF1β. Metabolic profiles, GSH quantification, HNF1β, and γ-glutamylcysteine ligase catalytic subunit (GCLC) and modifier subunit (GCLM) expression, cell cycle, and death were assessed in ES2 cell line (OCCC) and OVCAR3 cell line (OSC); HNF1β knockdown was performed in ES2 and murine model of subcutaneous and peritoneal OCCC tumors was established to test buthionine sulphoxamine (BSO), as a sensitizer to carboplatin. Glutaminolysis is activated in ES2 and OVCAR3, though ES2 exclusively synthesizes amino acids and GSH. ES2 cells are more resistant to carboplatin than OVCAR3 and the abrogation of GSH production by BSO sensitizes ES2 to carboplatin. HNF1β regulates the expression of GCLC, but not GCLM, and consequently GSH production in ES2. In vivo, BSO prior to carboplatin reduces dramatically subcutaneous tumor size and GSH levels, as well as peritoneal dissemination. Our study discloses HNF1β as the mediator of intrinsic OCCC chemoresistance and sheds a light to re-explore a cancer adjuvant therapeutic approach using BSO to overcome the lack of efficient therapy in OCCC.</p>',
'date' => '2015-10-31',
'pmid' => 'http://www.ncbi.nlm.nih.gov/pubmed/26520442',
'doi' => '10.1007/s13277-015-4290-5',
'modified' => '2016-01-19 07:13:46',
'created' => '2015-12-13 09:42:34',
'ProductsPublication' => array(
[maximum depth reached]
)
)
),
'Testimonial' => array(),
'Area' => array(),
'SafetySheet' => array()
)
$country = 'US'
$countries_allowed = array(
(int) 0 => 'CA',
(int) 1 => 'US',
(int) 2 => 'IE',
(int) 3 => 'GB',
(int) 4 => 'DK',
(int) 5 => 'NO',
(int) 6 => 'SE',
(int) 7 => 'FI',
(int) 8 => 'NL',
(int) 9 => 'BE',
(int) 10 => 'LU',
(int) 11 => 'FR',
(int) 12 => 'DE',
(int) 13 => 'CH',
(int) 14 => 'AT',
(int) 15 => 'ES',
(int) 16 => 'IT',
(int) 17 => 'PT'
)
$outsource = false
$other_formats = array()
$edit = ''
$testimonials = ''
$featured_testimonials = ''
$related_products = ''
$rrbs_service = array(
(int) 0 => (int) 1894,
(int) 1 => (int) 1895
)
$chipseq_service = array(
(int) 0 => (int) 2683,
(int) 1 => (int) 1835,
(int) 2 => (int) 1836,
(int) 3 => (int) 2684,
(int) 4 => (int) 1838,
(int) 5 => (int) 1839,
(int) 6 => (int) 1856
)
$labelize = object(Closure) {
}
$old_catalog_number = ''
$label = '<img src="/img/banners/banner-customizer-back.png" alt=""/>'
$document = array(
'id' => '677',
'name' => 'Custom Antibody 032010V4',
'description' => 'Datasheet description',
'image_id' => null,
'type' => 'Datasheet',
'url' => 'files/products/antibodies/Custom_Antibody_032010V4.pdf',
'slug' => 'custom-antibody-032010v4',
'meta_keywords' => null,
'meta_description' => null,
'modified' => '2015-07-07 11:47:44',
'created' => '2015-07-07 11:47:44',
'ProductsDocument' => array(
'id' => '1003',
'product_id' => '2651',
'document_id' => '677'
)
)
$publication = array(
'id' => '2804',
'name' => 'HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC)',
'authors' => 'Filipa Lopes-Coelho, Sofia Gouveia-Fernandes, Luís G Gonçalves, Carolina Nunes, Inês Faustino, Fernanda Silva, Ana Félix, Sofia A Pereira, Jacinta Serpa',
'description' => '<p>Chemoresistance to platinum-based antineoplastic agents is a consistent feature among ovarian carcinomas; however, whereas high-grade serous carcinoma (OSC) acquires resistance during chemotherapy, ovarian clear cell carcinoma (OCCC) is intrinsically resistant. The main objective of this study was to explore, in vitro and in vivo, if hepatocyte nuclear factor 1β (HNF1β) and glutaminolysis contribute for the resistance of OCCC to carboplatin through the intrinsically increased GSH bioavailability. To disclose the role of HNF1β, experiments were also performed in an OSC cell line, which does not express HNF1β. Metabolic profiles, GSH quantification, HNF1β, and γ-glutamylcysteine ligase catalytic subunit (GCLC) and modifier subunit (GCLM) expression, cell cycle, and death were assessed in ES2 cell line (OCCC) and OVCAR3 cell line (OSC); HNF1β knockdown was performed in ES2 and murine model of subcutaneous and peritoneal OCCC tumors was established to test buthionine sulphoxamine (BSO), as a sensitizer to carboplatin. Glutaminolysis is activated in ES2 and OVCAR3, though ES2 exclusively synthesizes amino acids and GSH. ES2 cells are more resistant to carboplatin than OVCAR3 and the abrogation of GSH production by BSO sensitizes ES2 to carboplatin. HNF1β regulates the expression of GCLC, but not GCLM, and consequently GSH production in ES2. In vivo, BSO prior to carboplatin reduces dramatically subcutaneous tumor size and GSH levels, as well as peritoneal dissemination. Our study discloses HNF1β as the mediator of intrinsic OCCC chemoresistance and sheds a light to re-explore a cancer adjuvant therapeutic approach using BSO to overcome the lack of efficient therapy in OCCC.</p>',
'date' => '2015-10-31',
'pmid' => 'http://www.ncbi.nlm.nih.gov/pubmed/26520442',
'doi' => '10.1007/s13277-015-4290-5',
'modified' => '2016-01-19 07:13:46',
'created' => '2015-12-13 09:42:34',
'ProductsPublication' => array(
'id' => '395',
'product_id' => '2651',
'publication_id' => '2804'
)
)
$externalLink = ' <a href="http://www.ncbi.nlm.nih.gov/pubmed/26520442" target="_blank"><i class="fa fa-external-link"></i></a>'include - APP/View/Products/view.ctp, line 755
View::_evaluate() - CORE/Cake/View/View.php, line 971
View::_render() - CORE/Cake/View/View.php, line 933
View::render() - CORE/Cake/View/View.php, line 473
Controller::render() - CORE/Cake/Controller/Controller.php, line 963
ProductsController::slug() - APP/Controller/ProductsController.php, line 1052
ReflectionMethod::invokeArgs() - [internal], line ??
Controller::invokeAction() - CORE/Cake/Controller/Controller.php, line 491
Dispatcher::_invoke() - CORE/Cake/Routing/Dispatcher.php, line 193
Dispatcher::dispatch() - CORE/Cake/Routing/Dispatcher.php, line 167
[main] - APP/webroot/index.php, line 118
Notice (8): Undefined variable: header [APP/View/Products/view.ctp, line 755]Code Context<!-- BEGIN: REQUEST_FORM MODAL -->
<div id="request_formModal" class="reveal-modal medium" data-reveal aria-labelledby="modalTitle" aria-hidden="true" role="dialog">
<?= $this->element('Forms/simple_form', array('solution_of_interest' => $solution_of_interest, 'header' => $header, 'message' => $message, 'campaign_id' => $campaign_id)) ?>
$viewFile = '/home/website-server/www/app/View/Products/view.ctp'
$dataForView = array(
'language' => 'en',
'meta_keywords' => 'Modification Ac-Lysine,custom epigenetic antibodies,diagenode',
'meta_description' => 'Diagenode offers Modification Ac-Lysine to meet your specific research needs.',
'meta_title' => 'Modification Ac-Lysine | Diagenode',
'product' => array(
'Product' => array(
'id' => '2651',
'antibody_id' => null,
'name' => 'Modification Ac-Lysine',
'description' => '<p><span>For many years, Diagenode has acquired a strong and reliable experience in the production of custom epigenetic antibodies, allowing us to become one of the most reliable partner in several EU projects in this field of studies. Following our success in optimizing and developing our epigenetic antibody production procedures we are able to offer this as a custom service to meet your specific research needs.</span></p>',
'label1' => 'Characteristics',
'info1' => '<ul>
<li><strong>Flexibility:</strong> you can provide us with your protein or with your own peptide or you can choose our custom peptide design/synthesis/coupling service.</li>
<li><strong>Support:</strong> our team of specialists will provide you with free peptide design and top-level advice and support along your immunisation program.</li>
<li><strong>High-Quality products:</strong> our extended immunisation program will ensure you to get more Ab with higher titer and affinity than any other supplier. Moreover at the end of the program you will receive the purified anti-serum.</li>
<li><strong>Extension of partnership:</strong> If you think that your antibody is proven to be of commercial interest, we will be pleased to consider the opportunity to collaborate.</li>
</ul>',
'label2' => '',
'info2' => '',
'label3' => '',
'info3' => '',
'format' => '20 mg',
'catalog_number' => 'pAb-cust-120',
'old_catalog_number' => '',
'sf_code' => '',
'type' => 'FRE',
'search_order' => '04-undefined',
'price_EUR' => '155',
'price_USD' => '185',
'price_GBP' => '140',
'price_JPY' => '26500',
'price_CNY' => '',
'price_AUD' => '460',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => true,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => true,
'last_datasheet_update' => '0000-00-00',
'slug' => 'modification-ac-lysine',
'meta_title' => 'Modification Ac-Lysine | Diagenode',
'meta_keywords' => 'Modification Ac-Lysine,custom epigenetic antibodies,diagenode',
'meta_description' => 'Diagenode offers Modification Ac-Lysine to meet your specific research needs.',
'modified' => '2023-11-24 11:00:49',
'created' => '2015-07-29 16:42:52',
'locale' => 'eng'
),
'Antibody' => array(
'host' => '*****',
'id' => null,
'name' => null,
'description' => null,
'clonality' => null,
'isotype' => null,
'lot' => null,
'concentration' => null,
'reactivity' => null,
'type' => null,
'purity' => null,
'classification' => null,
'application_table' => null,
'storage_conditions' => null,
'storage_buffer' => null,
'precautions' => null,
'uniprot_acc' => null,
'slug' => null,
'meta_keywords' => null,
'meta_description' => null,
'modified' => null,
'created' => null,
'select_label' => null
),
'Slave' => array(),
'Group' => array(),
'Related' => array(),
'Application' => array(),
'Category' => array(),
'Document' => array(
(int) 0 => array(
[maximum depth reached]
)
),
'Feature' => array(),
'Image' => array(
(int) 0 => array(
[maximum depth reached]
)
),
'Promotion' => array(),
'Protocol' => array(),
'Publication' => array(
(int) 0 => array(
[maximum depth reached]
)
),
'Testimonial' => array(),
'Area' => array(),
'SafetySheet' => array()
)
)
$language = 'en'
$meta_keywords = 'Modification Ac-Lysine,custom epigenetic antibodies,diagenode'
$meta_description = 'Diagenode offers Modification Ac-Lysine to meet your specific research needs.'
$meta_title = 'Modification Ac-Lysine | Diagenode'
$product = array(
'Product' => array(
'id' => '2651',
'antibody_id' => null,
'name' => 'Modification Ac-Lysine',
'description' => '<p><span>For many years, Diagenode has acquired a strong and reliable experience in the production of custom epigenetic antibodies, allowing us to become one of the most reliable partner in several EU projects in this field of studies. Following our success in optimizing and developing our epigenetic antibody production procedures we are able to offer this as a custom service to meet your specific research needs.</span></p>',
'label1' => 'Characteristics',
'info1' => '<ul>
<li><strong>Flexibility:</strong> you can provide us with your protein or with your own peptide or you can choose our custom peptide design/synthesis/coupling service.</li>
<li><strong>Support:</strong> our team of specialists will provide you with free peptide design and top-level advice and support along your immunisation program.</li>
<li><strong>High-Quality products:</strong> our extended immunisation program will ensure you to get more Ab with higher titer and affinity than any other supplier. Moreover at the end of the program you will receive the purified anti-serum.</li>
<li><strong>Extension of partnership:</strong> If you think that your antibody is proven to be of commercial interest, we will be pleased to consider the opportunity to collaborate.</li>
</ul>',
'label2' => '',
'info2' => '',
'label3' => '',
'info3' => '',
'format' => '20 mg',
'catalog_number' => 'pAb-cust-120',
'old_catalog_number' => '',
'sf_code' => '',
'type' => 'FRE',
'search_order' => '04-undefined',
'price_EUR' => '155',
'price_USD' => '185',
'price_GBP' => '140',
'price_JPY' => '26500',
'price_CNY' => '',
'price_AUD' => '460',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => true,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => true,
'last_datasheet_update' => '0000-00-00',
'slug' => 'modification-ac-lysine',
'meta_title' => 'Modification Ac-Lysine | Diagenode',
'meta_keywords' => 'Modification Ac-Lysine,custom epigenetic antibodies,diagenode',
'meta_description' => 'Diagenode offers Modification Ac-Lysine to meet your specific research needs.',
'modified' => '2023-11-24 11:00:49',
'created' => '2015-07-29 16:42:52',
'locale' => 'eng'
),
'Antibody' => array(
'host' => '*****',
'id' => null,
'name' => null,
'description' => null,
'clonality' => null,
'isotype' => null,
'lot' => null,
'concentration' => null,
'reactivity' => null,
'type' => null,
'purity' => null,
'classification' => null,
'application_table' => null,
'storage_conditions' => null,
'storage_buffer' => null,
'precautions' => null,
'uniprot_acc' => null,
'slug' => null,
'meta_keywords' => null,
'meta_description' => null,
'modified' => null,
'created' => null,
'select_label' => null
),
'Slave' => array(),
'Group' => array(),
'Related' => array(),
'Application' => array(),
'Category' => array(),
'Document' => array(
(int) 0 => array(
'id' => '677',
'name' => 'Custom Antibody 032010V4',
'description' => 'Datasheet description',
'image_id' => null,
'type' => 'Datasheet',
'url' => 'files/products/antibodies/Custom_Antibody_032010V4.pdf',
'slug' => 'custom-antibody-032010v4',
'meta_keywords' => null,
'meta_description' => null,
'modified' => '2015-07-07 11:47:44',
'created' => '2015-07-07 11:47:44',
'ProductsDocument' => array(
[maximum depth reached]
)
)
),
'Feature' => array(),
'Image' => array(
(int) 0 => array(
'id' => '250',
'name' => 'product/antibodies/antibody.png',
'alt' => 'Mouse IgG',
'modified' => '2020-11-27 07:00:09',
'created' => '2015-07-17 10:12:18',
'ProductsImage' => array(
[maximum depth reached]
)
)
),
'Promotion' => array(),
'Protocol' => array(),
'Publication' => array(
(int) 0 => array(
'id' => '2804',
'name' => 'HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC)',
'authors' => 'Filipa Lopes-Coelho, Sofia Gouveia-Fernandes, Luís G Gonçalves, Carolina Nunes, Inês Faustino, Fernanda Silva, Ana Félix, Sofia A Pereira, Jacinta Serpa',
'description' => '<p>Chemoresistance to platinum-based antineoplastic agents is a consistent feature among ovarian carcinomas; however, whereas high-grade serous carcinoma (OSC) acquires resistance during chemotherapy, ovarian clear cell carcinoma (OCCC) is intrinsically resistant. The main objective of this study was to explore, in vitro and in vivo, if hepatocyte nuclear factor 1β (HNF1β) and glutaminolysis contribute for the resistance of OCCC to carboplatin through the intrinsically increased GSH bioavailability. To disclose the role of HNF1β, experiments were also performed in an OSC cell line, which does not express HNF1β. Metabolic profiles, GSH quantification, HNF1β, and γ-glutamylcysteine ligase catalytic subunit (GCLC) and modifier subunit (GCLM) expression, cell cycle, and death were assessed in ES2 cell line (OCCC) and OVCAR3 cell line (OSC); HNF1β knockdown was performed in ES2 and murine model of subcutaneous and peritoneal OCCC tumors was established to test buthionine sulphoxamine (BSO), as a sensitizer to carboplatin. Glutaminolysis is activated in ES2 and OVCAR3, though ES2 exclusively synthesizes amino acids and GSH. ES2 cells are more resistant to carboplatin than OVCAR3 and the abrogation of GSH production by BSO sensitizes ES2 to carboplatin. HNF1β regulates the expression of GCLC, but not GCLM, and consequently GSH production in ES2. In vivo, BSO prior to carboplatin reduces dramatically subcutaneous tumor size and GSH levels, as well as peritoneal dissemination. Our study discloses HNF1β as the mediator of intrinsic OCCC chemoresistance and sheds a light to re-explore a cancer adjuvant therapeutic approach using BSO to overcome the lack of efficient therapy in OCCC.</p>',
'date' => '2015-10-31',
'pmid' => 'http://www.ncbi.nlm.nih.gov/pubmed/26520442',
'doi' => '10.1007/s13277-015-4290-5',
'modified' => '2016-01-19 07:13:46',
'created' => '2015-12-13 09:42:34',
'ProductsPublication' => array(
[maximum depth reached]
)
)
),
'Testimonial' => array(),
'Area' => array(),
'SafetySheet' => array()
)
$country = 'US'
$countries_allowed = array(
(int) 0 => 'CA',
(int) 1 => 'US',
(int) 2 => 'IE',
(int) 3 => 'GB',
(int) 4 => 'DK',
(int) 5 => 'NO',
(int) 6 => 'SE',
(int) 7 => 'FI',
(int) 8 => 'NL',
(int) 9 => 'BE',
(int) 10 => 'LU',
(int) 11 => 'FR',
(int) 12 => 'DE',
(int) 13 => 'CH',
(int) 14 => 'AT',
(int) 15 => 'ES',
(int) 16 => 'IT',
(int) 17 => 'PT'
)
$outsource = false
$other_formats = array()
$edit = ''
$testimonials = ''
$featured_testimonials = ''
$related_products = ''
$rrbs_service = array(
(int) 0 => (int) 1894,
(int) 1 => (int) 1895
)
$chipseq_service = array(
(int) 0 => (int) 2683,
(int) 1 => (int) 1835,
(int) 2 => (int) 1836,
(int) 3 => (int) 2684,
(int) 4 => (int) 1838,
(int) 5 => (int) 1839,
(int) 6 => (int) 1856
)
$labelize = object(Closure) {
}
$old_catalog_number = ''
$label = '<img src="/img/banners/banner-customizer-back.png" alt=""/>'
$document = array(
'id' => '677',
'name' => 'Custom Antibody 032010V4',
'description' => 'Datasheet description',
'image_id' => null,
'type' => 'Datasheet',
'url' => 'files/products/antibodies/Custom_Antibody_032010V4.pdf',
'slug' => 'custom-antibody-032010v4',
'meta_keywords' => null,
'meta_description' => null,
'modified' => '2015-07-07 11:47:44',
'created' => '2015-07-07 11:47:44',
'ProductsDocument' => array(
'id' => '1003',
'product_id' => '2651',
'document_id' => '677'
)
)
$publication = array(
'id' => '2804',
'name' => 'HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC)',
'authors' => 'Filipa Lopes-Coelho, Sofia Gouveia-Fernandes, Luís G Gonçalves, Carolina Nunes, Inês Faustino, Fernanda Silva, Ana Félix, Sofia A Pereira, Jacinta Serpa',
'description' => '<p>Chemoresistance to platinum-based antineoplastic agents is a consistent feature among ovarian carcinomas; however, whereas high-grade serous carcinoma (OSC) acquires resistance during chemotherapy, ovarian clear cell carcinoma (OCCC) is intrinsically resistant. The main objective of this study was to explore, in vitro and in vivo, if hepatocyte nuclear factor 1β (HNF1β) and glutaminolysis contribute for the resistance of OCCC to carboplatin through the intrinsically increased GSH bioavailability. To disclose the role of HNF1β, experiments were also performed in an OSC cell line, which does not express HNF1β. Metabolic profiles, GSH quantification, HNF1β, and γ-glutamylcysteine ligase catalytic subunit (GCLC) and modifier subunit (GCLM) expression, cell cycle, and death were assessed in ES2 cell line (OCCC) and OVCAR3 cell line (OSC); HNF1β knockdown was performed in ES2 and murine model of subcutaneous and peritoneal OCCC tumors was established to test buthionine sulphoxamine (BSO), as a sensitizer to carboplatin. Glutaminolysis is activated in ES2 and OVCAR3, though ES2 exclusively synthesizes amino acids and GSH. ES2 cells are more resistant to carboplatin than OVCAR3 and the abrogation of GSH production by BSO sensitizes ES2 to carboplatin. HNF1β regulates the expression of GCLC, but not GCLM, and consequently GSH production in ES2. In vivo, BSO prior to carboplatin reduces dramatically subcutaneous tumor size and GSH levels, as well as peritoneal dissemination. Our study discloses HNF1β as the mediator of intrinsic OCCC chemoresistance and sheds a light to re-explore a cancer adjuvant therapeutic approach using BSO to overcome the lack of efficient therapy in OCCC.</p>',
'date' => '2015-10-31',
'pmid' => 'http://www.ncbi.nlm.nih.gov/pubmed/26520442',
'doi' => '10.1007/s13277-015-4290-5',
'modified' => '2016-01-19 07:13:46',
'created' => '2015-12-13 09:42:34',
'ProductsPublication' => array(
'id' => '395',
'product_id' => '2651',
'publication_id' => '2804'
)
)
$externalLink = ' <a href="http://www.ncbi.nlm.nih.gov/pubmed/26520442" target="_blank"><i class="fa fa-external-link"></i></a>'include - APP/View/Products/view.ctp, line 755
View::_evaluate() - CORE/Cake/View/View.php, line 971
View::_render() - CORE/Cake/View/View.php, line 933
View::render() - CORE/Cake/View/View.php, line 473
Controller::render() - CORE/Cake/Controller/Controller.php, line 963
ProductsController::slug() - APP/Controller/ProductsController.php, line 1052
ReflectionMethod::invokeArgs() - [internal], line ??
Controller::invokeAction() - CORE/Cake/Controller/Controller.php, line 491
Dispatcher::_invoke() - CORE/Cake/Routing/Dispatcher.php, line 193
Dispatcher::dispatch() - CORE/Cake/Routing/Dispatcher.php, line 167
[main] - APP/webroot/index.php, line 118
Notice (8): Undefined variable: message [APP/View/Products/view.ctp, line 755]Code Context<!-- BEGIN: REQUEST_FORM MODAL -->
<div id="request_formModal" class="reveal-modal medium" data-reveal aria-labelledby="modalTitle" aria-hidden="true" role="dialog">
<?= $this->element('Forms/simple_form', array('solution_of_interest' => $solution_of_interest, 'header' => $header, 'message' => $message, 'campaign_id' => $campaign_id)) ?>
$viewFile = '/home/website-server/www/app/View/Products/view.ctp'
$dataForView = array(
'language' => 'en',
'meta_keywords' => 'Modification Ac-Lysine,custom epigenetic antibodies,diagenode',
'meta_description' => 'Diagenode offers Modification Ac-Lysine to meet your specific research needs.',
'meta_title' => 'Modification Ac-Lysine | Diagenode',
'product' => array(
'Product' => array(
'id' => '2651',
'antibody_id' => null,
'name' => 'Modification Ac-Lysine',
'description' => '<p><span>For many years, Diagenode has acquired a strong and reliable experience in the production of custom epigenetic antibodies, allowing us to become one of the most reliable partner in several EU projects in this field of studies. Following our success in optimizing and developing our epigenetic antibody production procedures we are able to offer this as a custom service to meet your specific research needs.</span></p>',
'label1' => 'Characteristics',
'info1' => '<ul>
<li><strong>Flexibility:</strong> you can provide us with your protein or with your own peptide or you can choose our custom peptide design/synthesis/coupling service.</li>
<li><strong>Support:</strong> our team of specialists will provide you with free peptide design and top-level advice and support along your immunisation program.</li>
<li><strong>High-Quality products:</strong> our extended immunisation program will ensure you to get more Ab with higher titer and affinity than any other supplier. Moreover at the end of the program you will receive the purified anti-serum.</li>
<li><strong>Extension of partnership:</strong> If you think that your antibody is proven to be of commercial interest, we will be pleased to consider the opportunity to collaborate.</li>
</ul>',
'label2' => '',
'info2' => '',
'label3' => '',
'info3' => '',
'format' => '20 mg',
'catalog_number' => 'pAb-cust-120',
'old_catalog_number' => '',
'sf_code' => '',
'type' => 'FRE',
'search_order' => '04-undefined',
'price_EUR' => '155',
'price_USD' => '185',
'price_GBP' => '140',
'price_JPY' => '26500',
'price_CNY' => '',
'price_AUD' => '460',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => true,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => true,
'last_datasheet_update' => '0000-00-00',
'slug' => 'modification-ac-lysine',
'meta_title' => 'Modification Ac-Lysine | Diagenode',
'meta_keywords' => 'Modification Ac-Lysine,custom epigenetic antibodies,diagenode',
'meta_description' => 'Diagenode offers Modification Ac-Lysine to meet your specific research needs.',
'modified' => '2023-11-24 11:00:49',
'created' => '2015-07-29 16:42:52',
'locale' => 'eng'
),
'Antibody' => array(
'host' => '*****',
'id' => null,
'name' => null,
'description' => null,
'clonality' => null,
'isotype' => null,
'lot' => null,
'concentration' => null,
'reactivity' => null,
'type' => null,
'purity' => null,
'classification' => null,
'application_table' => null,
'storage_conditions' => null,
'storage_buffer' => null,
'precautions' => null,
'uniprot_acc' => null,
'slug' => null,
'meta_keywords' => null,
'meta_description' => null,
'modified' => null,
'created' => null,
'select_label' => null
),
'Slave' => array(),
'Group' => array(),
'Related' => array(),
'Application' => array(),
'Category' => array(),
'Document' => array(
(int) 0 => array(
[maximum depth reached]
)
),
'Feature' => array(),
'Image' => array(
(int) 0 => array(
[maximum depth reached]
)
),
'Promotion' => array(),
'Protocol' => array(),
'Publication' => array(
(int) 0 => array(
[maximum depth reached]
)
),
'Testimonial' => array(),
'Area' => array(),
'SafetySheet' => array()
)
)
$language = 'en'
$meta_keywords = 'Modification Ac-Lysine,custom epigenetic antibodies,diagenode'
$meta_description = 'Diagenode offers Modification Ac-Lysine to meet your specific research needs.'
$meta_title = 'Modification Ac-Lysine | Diagenode'
$product = array(
'Product' => array(
'id' => '2651',
'antibody_id' => null,
'name' => 'Modification Ac-Lysine',
'description' => '<p><span>For many years, Diagenode has acquired a strong and reliable experience in the production of custom epigenetic antibodies, allowing us to become one of the most reliable partner in several EU projects in this field of studies. Following our success in optimizing and developing our epigenetic antibody production procedures we are able to offer this as a custom service to meet your specific research needs.</span></p>',
'label1' => 'Characteristics',
'info1' => '<ul>
<li><strong>Flexibility:</strong> you can provide us with your protein or with your own peptide or you can choose our custom peptide design/synthesis/coupling service.</li>
<li><strong>Support:</strong> our team of specialists will provide you with free peptide design and top-level advice and support along your immunisation program.</li>
<li><strong>High-Quality products:</strong> our extended immunisation program will ensure you to get more Ab with higher titer and affinity than any other supplier. Moreover at the end of the program you will receive the purified anti-serum.</li>
<li><strong>Extension of partnership:</strong> If you think that your antibody is proven to be of commercial interest, we will be pleased to consider the opportunity to collaborate.</li>
</ul>',
'label2' => '',
'info2' => '',
'label3' => '',
'info3' => '',
'format' => '20 mg',
'catalog_number' => 'pAb-cust-120',
'old_catalog_number' => '',
'sf_code' => '',
'type' => 'FRE',
'search_order' => '04-undefined',
'price_EUR' => '155',
'price_USD' => '185',
'price_GBP' => '140',
'price_JPY' => '26500',
'price_CNY' => '',
'price_AUD' => '460',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => true,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => true,
'last_datasheet_update' => '0000-00-00',
'slug' => 'modification-ac-lysine',
'meta_title' => 'Modification Ac-Lysine | Diagenode',
'meta_keywords' => 'Modification Ac-Lysine,custom epigenetic antibodies,diagenode',
'meta_description' => 'Diagenode offers Modification Ac-Lysine to meet your specific research needs.',
'modified' => '2023-11-24 11:00:49',
'created' => '2015-07-29 16:42:52',
'locale' => 'eng'
),
'Antibody' => array(
'host' => '*****',
'id' => null,
'name' => null,
'description' => null,
'clonality' => null,
'isotype' => null,
'lot' => null,
'concentration' => null,
'reactivity' => null,
'type' => null,
'purity' => null,
'classification' => null,
'application_table' => null,
'storage_conditions' => null,
'storage_buffer' => null,
'precautions' => null,
'uniprot_acc' => null,
'slug' => null,
'meta_keywords' => null,
'meta_description' => null,
'modified' => null,
'created' => null,
'select_label' => null
),
'Slave' => array(),
'Group' => array(),
'Related' => array(),
'Application' => array(),
'Category' => array(),
'Document' => array(
(int) 0 => array(
'id' => '677',
'name' => 'Custom Antibody 032010V4',
'description' => 'Datasheet description',
'image_id' => null,
'type' => 'Datasheet',
'url' => 'files/products/antibodies/Custom_Antibody_032010V4.pdf',
'slug' => 'custom-antibody-032010v4',
'meta_keywords' => null,
'meta_description' => null,
'modified' => '2015-07-07 11:47:44',
'created' => '2015-07-07 11:47:44',
'ProductsDocument' => array(
[maximum depth reached]
)
)
),
'Feature' => array(),
'Image' => array(
(int) 0 => array(
'id' => '250',
'name' => 'product/antibodies/antibody.png',
'alt' => 'Mouse IgG',
'modified' => '2020-11-27 07:00:09',
'created' => '2015-07-17 10:12:18',
'ProductsImage' => array(
[maximum depth reached]
)
)
),
'Promotion' => array(),
'Protocol' => array(),
'Publication' => array(
(int) 0 => array(
'id' => '2804',
'name' => 'HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC)',
'authors' => 'Filipa Lopes-Coelho, Sofia Gouveia-Fernandes, Luís G Gonçalves, Carolina Nunes, Inês Faustino, Fernanda Silva, Ana Félix, Sofia A Pereira, Jacinta Serpa',
'description' => '<p>Chemoresistance to platinum-based antineoplastic agents is a consistent feature among ovarian carcinomas; however, whereas high-grade serous carcinoma (OSC) acquires resistance during chemotherapy, ovarian clear cell carcinoma (OCCC) is intrinsically resistant. The main objective of this study was to explore, in vitro and in vivo, if hepatocyte nuclear factor 1β (HNF1β) and glutaminolysis contribute for the resistance of OCCC to carboplatin through the intrinsically increased GSH bioavailability. To disclose the role of HNF1β, experiments were also performed in an OSC cell line, which does not express HNF1β. Metabolic profiles, GSH quantification, HNF1β, and γ-glutamylcysteine ligase catalytic subunit (GCLC) and modifier subunit (GCLM) expression, cell cycle, and death were assessed in ES2 cell line (OCCC) and OVCAR3 cell line (OSC); HNF1β knockdown was performed in ES2 and murine model of subcutaneous and peritoneal OCCC tumors was established to test buthionine sulphoxamine (BSO), as a sensitizer to carboplatin. Glutaminolysis is activated in ES2 and OVCAR3, though ES2 exclusively synthesizes amino acids and GSH. ES2 cells are more resistant to carboplatin than OVCAR3 and the abrogation of GSH production by BSO sensitizes ES2 to carboplatin. HNF1β regulates the expression of GCLC, but not GCLM, and consequently GSH production in ES2. In vivo, BSO prior to carboplatin reduces dramatically subcutaneous tumor size and GSH levels, as well as peritoneal dissemination. Our study discloses HNF1β as the mediator of intrinsic OCCC chemoresistance and sheds a light to re-explore a cancer adjuvant therapeutic approach using BSO to overcome the lack of efficient therapy in OCCC.</p>',
'date' => '2015-10-31',
'pmid' => 'http://www.ncbi.nlm.nih.gov/pubmed/26520442',
'doi' => '10.1007/s13277-015-4290-5',
'modified' => '2016-01-19 07:13:46',
'created' => '2015-12-13 09:42:34',
'ProductsPublication' => array(
[maximum depth reached]
)
)
),
'Testimonial' => array(),
'Area' => array(),
'SafetySheet' => array()
)
$country = 'US'
$countries_allowed = array(
(int) 0 => 'CA',
(int) 1 => 'US',
(int) 2 => 'IE',
(int) 3 => 'GB',
(int) 4 => 'DK',
(int) 5 => 'NO',
(int) 6 => 'SE',
(int) 7 => 'FI',
(int) 8 => 'NL',
(int) 9 => 'BE',
(int) 10 => 'LU',
(int) 11 => 'FR',
(int) 12 => 'DE',
(int) 13 => 'CH',
(int) 14 => 'AT',
(int) 15 => 'ES',
(int) 16 => 'IT',
(int) 17 => 'PT'
)
$outsource = false
$other_formats = array()
$edit = ''
$testimonials = ''
$featured_testimonials = ''
$related_products = ''
$rrbs_service = array(
(int) 0 => (int) 1894,
(int) 1 => (int) 1895
)
$chipseq_service = array(
(int) 0 => (int) 2683,
(int) 1 => (int) 1835,
(int) 2 => (int) 1836,
(int) 3 => (int) 2684,
(int) 4 => (int) 1838,
(int) 5 => (int) 1839,
(int) 6 => (int) 1856
)
$labelize = object(Closure) {
}
$old_catalog_number = ''
$label = '<img src="/img/banners/banner-customizer-back.png" alt=""/>'
$document = array(
'id' => '677',
'name' => 'Custom Antibody 032010V4',
'description' => 'Datasheet description',
'image_id' => null,
'type' => 'Datasheet',
'url' => 'files/products/antibodies/Custom_Antibody_032010V4.pdf',
'slug' => 'custom-antibody-032010v4',
'meta_keywords' => null,
'meta_description' => null,
'modified' => '2015-07-07 11:47:44',
'created' => '2015-07-07 11:47:44',
'ProductsDocument' => array(
'id' => '1003',
'product_id' => '2651',
'document_id' => '677'
)
)
$publication = array(
'id' => '2804',
'name' => 'HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC)',
'authors' => 'Filipa Lopes-Coelho, Sofia Gouveia-Fernandes, Luís G Gonçalves, Carolina Nunes, Inês Faustino, Fernanda Silva, Ana Félix, Sofia A Pereira, Jacinta Serpa',
'description' => '<p>Chemoresistance to platinum-based antineoplastic agents is a consistent feature among ovarian carcinomas; however, whereas high-grade serous carcinoma (OSC) acquires resistance during chemotherapy, ovarian clear cell carcinoma (OCCC) is intrinsically resistant. The main objective of this study was to explore, in vitro and in vivo, if hepatocyte nuclear factor 1β (HNF1β) and glutaminolysis contribute for the resistance of OCCC to carboplatin through the intrinsically increased GSH bioavailability. To disclose the role of HNF1β, experiments were also performed in an OSC cell line, which does not express HNF1β. Metabolic profiles, GSH quantification, HNF1β, and γ-glutamylcysteine ligase catalytic subunit (GCLC) and modifier subunit (GCLM) expression, cell cycle, and death were assessed in ES2 cell line (OCCC) and OVCAR3 cell line (OSC); HNF1β knockdown was performed in ES2 and murine model of subcutaneous and peritoneal OCCC tumors was established to test buthionine sulphoxamine (BSO), as a sensitizer to carboplatin. Glutaminolysis is activated in ES2 and OVCAR3, though ES2 exclusively synthesizes amino acids and GSH. ES2 cells are more resistant to carboplatin than OVCAR3 and the abrogation of GSH production by BSO sensitizes ES2 to carboplatin. HNF1β regulates the expression of GCLC, but not GCLM, and consequently GSH production in ES2. In vivo, BSO prior to carboplatin reduces dramatically subcutaneous tumor size and GSH levels, as well as peritoneal dissemination. Our study discloses HNF1β as the mediator of intrinsic OCCC chemoresistance and sheds a light to re-explore a cancer adjuvant therapeutic approach using BSO to overcome the lack of efficient therapy in OCCC.</p>',
'date' => '2015-10-31',
'pmid' => 'http://www.ncbi.nlm.nih.gov/pubmed/26520442',
'doi' => '10.1007/s13277-015-4290-5',
'modified' => '2016-01-19 07:13:46',
'created' => '2015-12-13 09:42:34',
'ProductsPublication' => array(
'id' => '395',
'product_id' => '2651',
'publication_id' => '2804'
)
)
$externalLink = ' <a href="http://www.ncbi.nlm.nih.gov/pubmed/26520442" target="_blank"><i class="fa fa-external-link"></i></a>'include - APP/View/Products/view.ctp, line 755
View::_evaluate() - CORE/Cake/View/View.php, line 971
View::_render() - CORE/Cake/View/View.php, line 933
View::render() - CORE/Cake/View/View.php, line 473
Controller::render() - CORE/Cake/Controller/Controller.php, line 963
ProductsController::slug() - APP/Controller/ProductsController.php, line 1052
ReflectionMethod::invokeArgs() - [internal], line ??
Controller::invokeAction() - CORE/Cake/Controller/Controller.php, line 491
Dispatcher::_invoke() - CORE/Cake/Routing/Dispatcher.php, line 193
Dispatcher::dispatch() - CORE/Cake/Routing/Dispatcher.php, line 167
[main] - APP/webroot/index.php, line 118
Notice (8): Undefined variable: campaign_id [APP/View/Products/view.ctp, line 755]Code Context<!-- BEGIN: REQUEST_FORM MODAL -->
<div id="request_formModal" class="reveal-modal medium" data-reveal aria-labelledby="modalTitle" aria-hidden="true" role="dialog">
<?= $this->element('Forms/simple_form', array('solution_of_interest' => $solution_of_interest, 'header' => $header, 'message' => $message, 'campaign_id' => $campaign_id)) ?>
$viewFile = '/home/website-server/www/app/View/Products/view.ctp'
$dataForView = array(
'language' => 'en',
'meta_keywords' => 'Modification Ac-Lysine,custom epigenetic antibodies,diagenode',
'meta_description' => 'Diagenode offers Modification Ac-Lysine to meet your specific research needs.',
'meta_title' => 'Modification Ac-Lysine | Diagenode',
'product' => array(
'Product' => array(
'id' => '2651',
'antibody_id' => null,
'name' => 'Modification Ac-Lysine',
'description' => '<p><span>For many years, Diagenode has acquired a strong and reliable experience in the production of custom epigenetic antibodies, allowing us to become one of the most reliable partner in several EU projects in this field of studies. Following our success in optimizing and developing our epigenetic antibody production procedures we are able to offer this as a custom service to meet your specific research needs.</span></p>',
'label1' => 'Characteristics',
'info1' => '<ul>
<li><strong>Flexibility:</strong> you can provide us with your protein or with your own peptide or you can choose our custom peptide design/synthesis/coupling service.</li>
<li><strong>Support:</strong> our team of specialists will provide you with free peptide design and top-level advice and support along your immunisation program.</li>
<li><strong>High-Quality products:</strong> our extended immunisation program will ensure you to get more Ab with higher titer and affinity than any other supplier. Moreover at the end of the program you will receive the purified anti-serum.</li>
<li><strong>Extension of partnership:</strong> If you think that your antibody is proven to be of commercial interest, we will be pleased to consider the opportunity to collaborate.</li>
</ul>',
'label2' => '',
'info2' => '',
'label3' => '',
'info3' => '',
'format' => '20 mg',
'catalog_number' => 'pAb-cust-120',
'old_catalog_number' => '',
'sf_code' => '',
'type' => 'FRE',
'search_order' => '04-undefined',
'price_EUR' => '155',
'price_USD' => '185',
'price_GBP' => '140',
'price_JPY' => '26500',
'price_CNY' => '',
'price_AUD' => '460',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => true,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => true,
'last_datasheet_update' => '0000-00-00',
'slug' => 'modification-ac-lysine',
'meta_title' => 'Modification Ac-Lysine | Diagenode',
'meta_keywords' => 'Modification Ac-Lysine,custom epigenetic antibodies,diagenode',
'meta_description' => 'Diagenode offers Modification Ac-Lysine to meet your specific research needs.',
'modified' => '2023-11-24 11:00:49',
'created' => '2015-07-29 16:42:52',
'locale' => 'eng'
),
'Antibody' => array(
'host' => '*****',
'id' => null,
'name' => null,
'description' => null,
'clonality' => null,
'isotype' => null,
'lot' => null,
'concentration' => null,
'reactivity' => null,
'type' => null,
'purity' => null,
'classification' => null,
'application_table' => null,
'storage_conditions' => null,
'storage_buffer' => null,
'precautions' => null,
'uniprot_acc' => null,
'slug' => null,
'meta_keywords' => null,
'meta_description' => null,
'modified' => null,
'created' => null,
'select_label' => null
),
'Slave' => array(),
'Group' => array(),
'Related' => array(),
'Application' => array(),
'Category' => array(),
'Document' => array(
(int) 0 => array(
[maximum depth reached]
)
),
'Feature' => array(),
'Image' => array(
(int) 0 => array(
[maximum depth reached]
)
),
'Promotion' => array(),
'Protocol' => array(),
'Publication' => array(
(int) 0 => array(
[maximum depth reached]
)
),
'Testimonial' => array(),
'Area' => array(),
'SafetySheet' => array()
)
)
$language = 'en'
$meta_keywords = 'Modification Ac-Lysine,custom epigenetic antibodies,diagenode'
$meta_description = 'Diagenode offers Modification Ac-Lysine to meet your specific research needs.'
$meta_title = 'Modification Ac-Lysine | Diagenode'
$product = array(
'Product' => array(
'id' => '2651',
'antibody_id' => null,
'name' => 'Modification Ac-Lysine',
'description' => '<p><span>For many years, Diagenode has acquired a strong and reliable experience in the production of custom epigenetic antibodies, allowing us to become one of the most reliable partner in several EU projects in this field of studies. Following our success in optimizing and developing our epigenetic antibody production procedures we are able to offer this as a custom service to meet your specific research needs.</span></p>',
'label1' => 'Characteristics',
'info1' => '<ul>
<li><strong>Flexibility:</strong> you can provide us with your protein or with your own peptide or you can choose our custom peptide design/synthesis/coupling service.</li>
<li><strong>Support:</strong> our team of specialists will provide you with free peptide design and top-level advice and support along your immunisation program.</li>
<li><strong>High-Quality products:</strong> our extended immunisation program will ensure you to get more Ab with higher titer and affinity than any other supplier. Moreover at the end of the program you will receive the purified anti-serum.</li>
<li><strong>Extension of partnership:</strong> If you think that your antibody is proven to be of commercial interest, we will be pleased to consider the opportunity to collaborate.</li>
</ul>',
'label2' => '',
'info2' => '',
'label3' => '',
'info3' => '',
'format' => '20 mg',
'catalog_number' => 'pAb-cust-120',
'old_catalog_number' => '',
'sf_code' => '',
'type' => 'FRE',
'search_order' => '04-undefined',
'price_EUR' => '155',
'price_USD' => '185',
'price_GBP' => '140',
'price_JPY' => '26500',
'price_CNY' => '',
'price_AUD' => '460',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => true,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => true,
'last_datasheet_update' => '0000-00-00',
'slug' => 'modification-ac-lysine',
'meta_title' => 'Modification Ac-Lysine | Diagenode',
'meta_keywords' => 'Modification Ac-Lysine,custom epigenetic antibodies,diagenode',
'meta_description' => 'Diagenode offers Modification Ac-Lysine to meet your specific research needs.',
'modified' => '2023-11-24 11:00:49',
'created' => '2015-07-29 16:42:52',
'locale' => 'eng'
),
'Antibody' => array(
'host' => '*****',
'id' => null,
'name' => null,
'description' => null,
'clonality' => null,
'isotype' => null,
'lot' => null,
'concentration' => null,
'reactivity' => null,
'type' => null,
'purity' => null,
'classification' => null,
'application_table' => null,
'storage_conditions' => null,
'storage_buffer' => null,
'precautions' => null,
'uniprot_acc' => null,
'slug' => null,
'meta_keywords' => null,
'meta_description' => null,
'modified' => null,
'created' => null,
'select_label' => null
),
'Slave' => array(),
'Group' => array(),
'Related' => array(),
'Application' => array(),
'Category' => array(),
'Document' => array(
(int) 0 => array(
'id' => '677',
'name' => 'Custom Antibody 032010V4',
'description' => 'Datasheet description',
'image_id' => null,
'type' => 'Datasheet',
'url' => 'files/products/antibodies/Custom_Antibody_032010V4.pdf',
'slug' => 'custom-antibody-032010v4',
'meta_keywords' => null,
'meta_description' => null,
'modified' => '2015-07-07 11:47:44',
'created' => '2015-07-07 11:47:44',
'ProductsDocument' => array(
[maximum depth reached]
)
)
),
'Feature' => array(),
'Image' => array(
(int) 0 => array(
'id' => '250',
'name' => 'product/antibodies/antibody.png',
'alt' => 'Mouse IgG',
'modified' => '2020-11-27 07:00:09',
'created' => '2015-07-17 10:12:18',
'ProductsImage' => array(
[maximum depth reached]
)
)
),
'Promotion' => array(),
'Protocol' => array(),
'Publication' => array(
(int) 0 => array(
'id' => '2804',
'name' => 'HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC)',
'authors' => 'Filipa Lopes-Coelho, Sofia Gouveia-Fernandes, Luís G Gonçalves, Carolina Nunes, Inês Faustino, Fernanda Silva, Ana Félix, Sofia A Pereira, Jacinta Serpa',
'description' => '<p>Chemoresistance to platinum-based antineoplastic agents is a consistent feature among ovarian carcinomas; however, whereas high-grade serous carcinoma (OSC) acquires resistance during chemotherapy, ovarian clear cell carcinoma (OCCC) is intrinsically resistant. The main objective of this study was to explore, in vitro and in vivo, if hepatocyte nuclear factor 1β (HNF1β) and glutaminolysis contribute for the resistance of OCCC to carboplatin through the intrinsically increased GSH bioavailability. To disclose the role of HNF1β, experiments were also performed in an OSC cell line, which does not express HNF1β. Metabolic profiles, GSH quantification, HNF1β, and γ-glutamylcysteine ligase catalytic subunit (GCLC) and modifier subunit (GCLM) expression, cell cycle, and death were assessed in ES2 cell line (OCCC) and OVCAR3 cell line (OSC); HNF1β knockdown was performed in ES2 and murine model of subcutaneous and peritoneal OCCC tumors was established to test buthionine sulphoxamine (BSO), as a sensitizer to carboplatin. Glutaminolysis is activated in ES2 and OVCAR3, though ES2 exclusively synthesizes amino acids and GSH. ES2 cells are more resistant to carboplatin than OVCAR3 and the abrogation of GSH production by BSO sensitizes ES2 to carboplatin. HNF1β regulates the expression of GCLC, but not GCLM, and consequently GSH production in ES2. In vivo, BSO prior to carboplatin reduces dramatically subcutaneous tumor size and GSH levels, as well as peritoneal dissemination. Our study discloses HNF1β as the mediator of intrinsic OCCC chemoresistance and sheds a light to re-explore a cancer adjuvant therapeutic approach using BSO to overcome the lack of efficient therapy in OCCC.</p>',
'date' => '2015-10-31',
'pmid' => 'http://www.ncbi.nlm.nih.gov/pubmed/26520442',
'doi' => '10.1007/s13277-015-4290-5',
'modified' => '2016-01-19 07:13:46',
'created' => '2015-12-13 09:42:34',
'ProductsPublication' => array(
[maximum depth reached]
)
)
),
'Testimonial' => array(),
'Area' => array(),
'SafetySheet' => array()
)
$country = 'US'
$countries_allowed = array(
(int) 0 => 'CA',
(int) 1 => 'US',
(int) 2 => 'IE',
(int) 3 => 'GB',
(int) 4 => 'DK',
(int) 5 => 'NO',
(int) 6 => 'SE',
(int) 7 => 'FI',
(int) 8 => 'NL',
(int) 9 => 'BE',
(int) 10 => 'LU',
(int) 11 => 'FR',
(int) 12 => 'DE',
(int) 13 => 'CH',
(int) 14 => 'AT',
(int) 15 => 'ES',
(int) 16 => 'IT',
(int) 17 => 'PT'
)
$outsource = false
$other_formats = array()
$edit = ''
$testimonials = ''
$featured_testimonials = ''
$related_products = ''
$rrbs_service = array(
(int) 0 => (int) 1894,
(int) 1 => (int) 1895
)
$chipseq_service = array(
(int) 0 => (int) 2683,
(int) 1 => (int) 1835,
(int) 2 => (int) 1836,
(int) 3 => (int) 2684,
(int) 4 => (int) 1838,
(int) 5 => (int) 1839,
(int) 6 => (int) 1856
)
$labelize = object(Closure) {
}
$old_catalog_number = ''
$label = '<img src="/img/banners/banner-customizer-back.png" alt=""/>'
$document = array(
'id' => '677',
'name' => 'Custom Antibody 032010V4',
'description' => 'Datasheet description',
'image_id' => null,
'type' => 'Datasheet',
'url' => 'files/products/antibodies/Custom_Antibody_032010V4.pdf',
'slug' => 'custom-antibody-032010v4',
'meta_keywords' => null,
'meta_description' => null,
'modified' => '2015-07-07 11:47:44',
'created' => '2015-07-07 11:47:44',
'ProductsDocument' => array(
'id' => '1003',
'product_id' => '2651',
'document_id' => '677'
)
)
$publication = array(
'id' => '2804',
'name' => 'HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC)',
'authors' => 'Filipa Lopes-Coelho, Sofia Gouveia-Fernandes, Luís G Gonçalves, Carolina Nunes, Inês Faustino, Fernanda Silva, Ana Félix, Sofia A Pereira, Jacinta Serpa',
'description' => '<p>Chemoresistance to platinum-based antineoplastic agents is a consistent feature among ovarian carcinomas; however, whereas high-grade serous carcinoma (OSC) acquires resistance during chemotherapy, ovarian clear cell carcinoma (OCCC) is intrinsically resistant. The main objective of this study was to explore, in vitro and in vivo, if hepatocyte nuclear factor 1β (HNF1β) and glutaminolysis contribute for the resistance of OCCC to carboplatin through the intrinsically increased GSH bioavailability. To disclose the role of HNF1β, experiments were also performed in an OSC cell line, which does not express HNF1β. Metabolic profiles, GSH quantification, HNF1β, and γ-glutamylcysteine ligase catalytic subunit (GCLC) and modifier subunit (GCLM) expression, cell cycle, and death were assessed in ES2 cell line (OCCC) and OVCAR3 cell line (OSC); HNF1β knockdown was performed in ES2 and murine model of subcutaneous and peritoneal OCCC tumors was established to test buthionine sulphoxamine (BSO), as a sensitizer to carboplatin. Glutaminolysis is activated in ES2 and OVCAR3, though ES2 exclusively synthesizes amino acids and GSH. ES2 cells are more resistant to carboplatin than OVCAR3 and the abrogation of GSH production by BSO sensitizes ES2 to carboplatin. HNF1β regulates the expression of GCLC, but not GCLM, and consequently GSH production in ES2. In vivo, BSO prior to carboplatin reduces dramatically subcutaneous tumor size and GSH levels, as well as peritoneal dissemination. Our study discloses HNF1β as the mediator of intrinsic OCCC chemoresistance and sheds a light to re-explore a cancer adjuvant therapeutic approach using BSO to overcome the lack of efficient therapy in OCCC.</p>',
'date' => '2015-10-31',
'pmid' => 'http://www.ncbi.nlm.nih.gov/pubmed/26520442',
'doi' => '10.1007/s13277-015-4290-5',
'modified' => '2016-01-19 07:13:46',
'created' => '2015-12-13 09:42:34',
'ProductsPublication' => array(
'id' => '395',
'product_id' => '2651',
'publication_id' => '2804'
)
)
$externalLink = ' <a href="http://www.ncbi.nlm.nih.gov/pubmed/26520442" target="_blank"><i class="fa fa-external-link"></i></a>'include - APP/View/Products/view.ctp, line 755
View::_evaluate() - CORE/Cake/View/View.php, line 971
View::_render() - CORE/Cake/View/View.php, line 933
View::render() - CORE/Cake/View/View.php, line 473
Controller::render() - CORE/Cake/Controller/Controller.php, line 963
ProductsController::slug() - APP/Controller/ProductsController.php, line 1052
ReflectionMethod::invokeArgs() - [internal], line ??
Controller::invokeAction() - CORE/Cake/Controller/Controller.php, line 491
Dispatcher::_invoke() - CORE/Cake/Routing/Dispatcher.php, line 193
Dispatcher::dispatch() - CORE/Cake/Routing/Dispatcher.php, line 167
[main] - APP/webroot/index.php, line 118
×
